<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01930461</url>
  </required_header>
  <id_info>
    <org_study_id>VO72.12</org_study_id>
    <nct_id>NCT01930461</nct_id>
  </id_info>
  <brief_title>Dose Ranging Study of SLIT Tablets of House Dust Mite Allergen Extracts (HDM) in Adults With HDM-associated Allergic Asthma</brief_title>
  <official_title>A Dose Ranging Study Investigating the Efficacy and Safety of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts in Adults With House Dust Mite-associated Allergic Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stallergenes Greer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stallergenes Greer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the efficacy and safety of different doses of&#xD;
      sublingual tablets of house dust mite allergen extracts as compared to placebo in adults with&#xD;
      house dust mite-associated allergic asthma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect on the Asthma control test (ACT) score</measure>
    <time_frame>13 months</time_frame>
    <description>Assessment of the effect of one year of treatment of 3 different doses of sublingual immunotherapy tablets of house dust mite (HDM) allergen extracts as compared to placebo on the Asthma Control Test™ (ACT) score, in adults with HDM-associated allergic asthma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number and percentage of subjects with treatment-emergent AEs</measure>
    <time_frame>Measured during 13 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes of Immunological parameters (HDM-specific IgE and IgG4 values)</measure>
    <time_frame>13 months</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">386</enrollment>
  <condition>Asthma</condition>
  <condition>House Dust Mite Allergy</condition>
  <arm_group>
    <arm_group_label>SLIT (A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SLIT tablets of HDM allergen extracts, 3 different doses (A)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SLIT (B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SLIT tablets of HDM allergen extracts, 3 different doses (B)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SLIT (C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SLIT tablets of HDM allergen extracts, 3 different doses (C)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo matching the SLIT tablets of HDM allergen extracts</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SLIT tablets of HDM allergen extracts, 3 different doses (A)</intervention_name>
    <description>Two sublingual tablets daily for 13 months</description>
    <arm_group_label>SLIT (A)</arm_group_label>
    <other_name>Sublingual immunotherapy tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SLIT tablets of HDM allergen extracts, 3 different doses (B)</intervention_name>
    <description>Two sublingual tablets daily for 13 months</description>
    <arm_group_label>SLIT (B)</arm_group_label>
    <other_name>Sublingual immunotherapy tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SLIT tablets of HDM allergen extracts, 3 different doses (C)</intervention_name>
    <description>Two sublingual tablets daily for 13 months</description>
    <arm_group_label>SLIT (C)</arm_group_label>
    <other_name>Sublingual immunotherapy tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo matching the SLIT tablets of HDM allergen extracts</intervention_name>
    <description>Two sublingual tablets daily for 13 months</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sublingual placebo tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent.&#xD;
&#xD;
          -  Male or female from 18 to 50 years of age.&#xD;
&#xD;
          -  Diagnosed asthma and rhinitis with medical history consistent with HDM-induced&#xD;
             allergic asthma and rhinitis.&#xD;
&#xD;
          -  Positive SPT to HDM and and HDM-specific IgE serum value ≥ 0.7 kU/L.&#xD;
&#xD;
          -  Stable asthma therapies.&#xD;
&#xD;
          -  Spirometry (pre-bronchodilator) with best FEV1 ≥ 70% of the predicted value.&#xD;
&#xD;
          -  Spirometry with reversibility in FEV1 of ≥ 12% and ≥ 200 mL.&#xD;
&#xD;
          -  Asthma Control Test™ (ACT) score ≤ 19.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Former smoker with &gt; 10 pack year history or current smoker.&#xD;
&#xD;
          -  Patient with a urine level of cotinine ≥ 500 ng/mL.&#xD;
&#xD;
          -  Co-sensitisation to any allergen possibly leading to clinically relevant symptoms&#xD;
             likely to significantly change the asthma symptoms of the subject during the study.&#xD;
&#xD;
          -  Patient who received allergen immunotherapy for HDM within the past 10 years.&#xD;
&#xD;
          -  Ongoing immunotherapy for an aeroallergen other than house dust mite.&#xD;
&#xD;
          -  Patient with any oral condition that could confound the safety assessments or planning&#xD;
             to have a dental extraction during the study.&#xD;
&#xD;
          -  Patient treated with beta-blockers, tricyclic antidepressants or monoamine oxidase&#xD;
             inhibitors (MAOIs).&#xD;
&#xD;
          -  Pregnant women or breast-feeding/lactating.&#xD;
&#xD;
          -  Women with childbearing potential who are not using a medically accepted birth control&#xD;
             method.&#xD;
&#xD;
          -  Patient with a past or current disease, which as judged by the Investigator, may&#xD;
             affect the patient's participation in, or the outcome of this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pascal Demoly, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montpellier, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Arnaud de Villeneuve</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHC, Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Berlin - Allergie-Centrum-Charité</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPZOZ Uniwersytecki Szpital Kliniczny Nr 1im.N.Barlickiego w Uniwersystetu Medycznego w Łodzi</name>
      <address>
        <city>Lodz</city>
        <zip>90-153</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Majorek-Olechowska Bernadetta</name>
      <address>
        <city>Tarnow</city>
        <zip>33-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>August 16, 2013</study_first_submitted>
  <study_first_submitted_qc>August 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2013</study_first_posted>
  <last_update_submitted>December 17, 2015</last_update_submitted>
  <last_update_submitted_qc>December 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Factors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

